ATE287210T1 - Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen - Google Patents

Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen

Info

Publication number
ATE287210T1
ATE287210T1 AT95939848T AT95939848T ATE287210T1 AT E287210 T1 ATE287210 T1 AT E287210T1 AT 95939848 T AT95939848 T AT 95939848T AT 95939848 T AT95939848 T AT 95939848T AT E287210 T1 ATE287210 T1 AT E287210T1
Authority
AT
Austria
Prior art keywords
treatment
active ingredients
red blood
blood cell
methods
Prior art date
Application number
AT95939848T
Other languages
English (en)
Inventor
David Cook
Susan Wollowitz
Aileen Niero
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp filed Critical Cerus Corp
Application granted granted Critical
Publication of ATE287210T1 publication Critical patent/ATE287210T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C07D219/12—Amino-alkylamino radicals attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10161—Methods of inactivation or attenuation
    • C12N2730/10163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18161—Methods of inactivation or attenuation
    • C12N2795/18163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95939848T 1994-11-14 1995-11-08 Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen ATE287210T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/338,040 US5691132A (en) 1994-11-14 1994-11-14 Method for inactivating pathogens in red cell compositions using quinacrine mustard
PCT/US1995/014550 WO1996014737A1 (en) 1994-11-14 1995-11-08 Treating red blood cell solutions with anti-viral agents

Publications (1)

Publication Number Publication Date
ATE287210T1 true ATE287210T1 (de) 2005-02-15

Family

ID=23323153

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95939848T ATE287210T1 (de) 1994-11-14 1995-11-08 Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen

Country Status (8)

Country Link
US (6) US5691132A (de)
EP (1) EP0804074B1 (de)
JP (1) JP3145124B2 (de)
AT (1) ATE287210T1 (de)
AU (1) AU712034B2 (de)
CA (1) CA2203885C (de)
DE (1) DE69533942T2 (de)
WO (1) WO1996014737A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4107396A (en) * 1992-03-02 1996-06-06 Cerus Corporation Synthetic media for blood components
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
DE4444045C2 (de) * 1994-12-10 1997-04-17 Behringwerke Ag Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten
US6544727B1 (en) 1995-06-07 2003-04-08 Cerus Corporation Methods and devices for the removal of psoralens from blood products
US20040048235A1 (en) * 1995-08-29 2004-03-11 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
FR2753536B1 (fr) * 1996-09-16 1998-11-20 Aetsrn Procede d'evaluation de la phagocytose de cellules cibles par des macrophages in vitro ; applications diagnostiques et application au controle de qualite de stocks de cellules
US5922278A (en) * 1996-11-19 1999-07-13 Baxter International Inc. Method and apparatus for inactivating contaminants in biological fluid
US6190609B1 (en) 1996-11-19 2001-02-20 Baxter International Inc. Methods and apparatus for inactivating contaminants in biological fluid
EP1364944A1 (de) * 1997-01-06 2003-11-26 Cerus Corporation Verbindungen mit leicht spaltbaren Bindungen zur Inaktivierung von Pathogenen
US20010009756A1 (en) 1998-01-06 2001-07-26 Derek Hei Flow devices for the reduction of compounds from biological compositions and methods of use
US20010018179A1 (en) 1998-01-06 2001-08-30 Derek J. Hei Batch devices for the reduction of compounds from biological compositions containing cells and methods of use
CN101676268B (zh) * 1997-01-06 2013-09-25 塞鲁斯公司 用于病原体灭活的脆性化合物
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
US6514987B1 (en) * 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6352695B1 (en) 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
DE69819360T2 (de) * 1997-11-20 2004-08-19 Cerus Corp., Concord Neue psoralene zur inaktivierung von pathogenen
WO1999034839A1 (en) * 1998-01-06 1999-07-15 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
US7611831B2 (en) * 1998-01-06 2009-11-03 Cerus Corporation Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
EP1085880A2 (de) 1998-06-11 2001-03-28 Cerus Corporation Verwendung von alkylierungsmitteln zur hemmung der proliferation von glatten muskelzellen
US6099734A (en) * 1998-07-08 2000-08-08 Baxter International Inc. Apparatus, membranes and methods for removing organic compounds from a biological fluid
US6908553B1 (en) 1998-07-08 2005-06-21 Baxter International Inc. Composite membrane with particulate matter substantially immobilized therein
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US20070099170A1 (en) * 1998-07-21 2007-05-03 Navigant Biotechnologies, Inc. Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate
US6277337B1 (en) 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
US6565802B1 (en) 1999-06-03 2003-05-20 Baxter International Inc. Apparatus, systems and methods for processing and treating a biological fluid with light
US7445756B2 (en) 1999-06-03 2008-11-04 Fenwal, Inc. Fluid processing sets and organizers for the same
US7025877B1 (en) 1999-06-03 2006-04-11 Baxter International Inc. Processing set for processing and treating a biological fluid
US7068361B2 (en) 1999-06-03 2006-06-27 Baxter International Apparatus, systems and methods for processing and treating a biological fluid with light
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US7985588B2 (en) 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
TW590780B (en) 2000-06-02 2004-06-11 Gambro Inc Additive solutions containing riboflavin
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
ES2306731T3 (es) * 2000-10-17 2008-11-16 Zeptometrix Corporation Microorganismos que se han hecho no patogenos.
DE10051628B4 (de) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Einzelsträngiges Oligonukleotid und dessen Verwendung
US6548241B1 (en) * 2000-11-28 2003-04-15 Gambro, Inc. Storage solution containing photosensitizer for inactivation of biological contaminants
EP1365750A2 (de) * 2000-12-21 2003-12-03 Cerus Corporation Methoden zur inaktivierung von pathogenen in biomaterialien
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
US7381976B2 (en) 2001-03-13 2008-06-03 Triton Thalassic Technologies, Inc. Monochromatic fluid treatment systems
US20030031584A1 (en) * 2001-08-10 2003-02-13 Wilson Burgess Methods for sterilizing biological materials using dipeptide stabilizers
US7235392B2 (en) * 2001-12-07 2007-06-26 The Ohio State University Research Foundation Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder
US7745180B2 (en) * 2002-04-24 2010-06-29 Hitachi Chemical Co., Ltd. Device and method for high-throughput quantification of mRNA from whole blood
WO2004043338A2 (en) * 2002-05-10 2004-05-27 The Ohio State University Flavin n-oxides: new anti-cancer agents and pathogen eradication agents
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
EP1575500A4 (de) * 2002-07-12 2007-01-03 Univ Johns Hopkins Mesothelin-vakzine und model systems
CA2499355C (en) * 2002-09-18 2012-07-17 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for detection of an antigen on a cell and in a biological mixture
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
CA2515369C (en) * 2003-02-06 2015-03-31 Cerus Corporation Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
AU2004224425B2 (en) * 2003-02-06 2010-06-24 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7534348B2 (en) * 2003-09-12 2009-05-19 Fenwal, Inc. Flow-through removal device and system using such device
US20050137517A1 (en) 2003-12-19 2005-06-23 Baxter International Inc. Processing systems and methods for providing leukocyte-reduced blood components conditioned for pathogen inactivation
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2006029233A2 (en) * 2004-09-07 2006-03-16 Zymequest, Inc. Apparatus for prolonging survival of platelets
WO2007047687A2 (en) * 2005-10-14 2007-04-26 Zymequest, Inc. Compositions and methods for prolonging survival of platelets
CN103961731B (zh) * 2004-10-29 2017-01-18 塞鲁斯公司 用于红细胞灭活过程的改进的猝灭方法
DE102007038513A1 (de) 2007-08-16 2009-02-19 Robert Bosch Gmbh Monostatischer Mehrstrahlradarsensor für Kraftfahrzeuge
WO2009054182A1 (ja) 2007-10-25 2009-04-30 Fuji Electric Holdings Co., Ltd. スピンバルブ素子及びその製造方法
CN102046006B (zh) 2008-04-09 2014-09-24 塞鲁斯公司 用于红细胞病原体灭活的改进猝灭方法
AU2009249273A1 (en) 2008-05-19 2009-11-26 Aduro Biotech Compositions comprising PrfA*mutant listeria and methods of use thereof
WO2010107789A1 (en) * 2009-03-17 2010-09-23 Marv Enterprises Llc Sequential extracorporeal treatment of bodily fluids
JP6189751B2 (ja) 2010-12-30 2017-08-30 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 病原体不活性化剤としてのグリコール
WO2013148405A2 (en) * 2012-03-27 2013-10-03 Felder Mitchell S Treatment for atherosclerosis
EP2855504B1 (de) 2012-05-31 2018-10-24 Agency For Science, Technology And Research Chromatografische reinigung von immunglobulin-g-zubereitungen mit teilchen mit multimodalen funktionalitäten
WO2013180648A1 (en) 2012-05-31 2013-12-05 Agency For Science, Technology And Research Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations
EP2855502B1 (de) 2012-05-31 2019-06-26 Agency For Science, Technology And Research Verfahren zur reduzierung des gehalts an proteinverunreinigskomplexen und -aggregaten in proteinpräparaten durch behandlung mit elektropositiven organischen additiven
SG11201505195TA (en) 2013-02-06 2015-08-28 Agency Science Tech & Res Methods For Reducing Aggregate Content In Protein Preparations
EP3194576B1 (de) 2014-07-23 2020-11-18 Cerus Corporation Verfahren zur herstellung von thrombozyten-produkten
DE202015100806U1 (de) 2015-02-19 2015-04-15 Paul Schaffrath Vorrichtung zur Inaktivierung von Krankheitserregern in Flüssigkeiten
EP3313418B1 (de) 2015-06-26 2024-03-13 Cerus Corporation Kryopräzipitatzusammensetzungen und verfahren zur herstellung davon
EP3364986B1 (de) 2015-10-23 2023-12-13 Cerus Corporation Pathogen-inaktiviertes kryoarmes plasma und verfahren zur verwendung davon
US20190369087A1 (en) * 2016-12-23 2019-12-05 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
EP3562493A1 (de) 2016-12-31 2019-11-06 Cerus Corporation Zusammensetzungen und verfahren zur herstellung von erythrozyten
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
CN116571191A (zh) 2017-12-29 2023-08-11 塞鲁斯公司 用于处理生物流体的系统和方法
IL281504B1 (en) 2018-09-20 2024-04-01 Cerus Corp Methods and kits for preparing pathogen-neutralized whole blood
CA3143732A1 (en) 2019-06-28 2020-12-30 Cerus Corporation System and methods for implementing a biological fluid treatment device

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE444045C (de) 1925-10-20 1927-05-13 Ernst Kaempfer Verfahren zur Herstellung von Schweissdraht
US3819270A (en) * 1972-10-02 1974-06-25 Block Engineering Blood cell analyzer
US4124598A (en) * 1976-10-20 1978-11-07 Hoffmann-La Roche Inc. Psoralens
US4196281A (en) * 1976-10-20 1980-04-01 Regents Of The University Of California Psoralens
US4182750A (en) * 1977-04-21 1980-01-08 Sullivan Thomas E Bloodcompatible functional polymers
US4107182A (en) * 1977-07-29 1978-08-15 Hoffmann-La Roche Inc. 7-Oxo-9-methoxy-7H-furo[3,2-g][1]benzopyran-6-carboxylic acid
US4252653A (en) * 1978-08-25 1981-02-24 Stolle Research And Development Corporation Hemoperfusion device for specific modification or removal of components of whole blood
US4269852A (en) * 1979-09-10 1981-05-26 Thomas C. Elder, Inc. 4'-Substituted-4,5',8-trialkylpsoralens
US4269851A (en) * 1979-09-10 1981-05-26 Thomas C. Elder, Inc. 8-Aminoalkyl-4-alkylpsoralens
US4370344A (en) * 1979-09-10 1983-01-25 Elder Pharmaceuticals, Inc. 5'-Aminoalkyl-4'-alkylpsoralens
US4298614A (en) * 1979-09-10 1981-11-03 Thomas C. Elder, Inc. 5'-Aminoalkyl-4',4-dialkylpsoralens
US4294822A (en) 1980-07-29 1981-10-13 Thomas C. Elder, Inc. 5-Aminoalkyl-4,4,8-trialkylpsoralens
US4613322A (en) * 1982-12-08 1986-09-23 Edelson Richard Leslie Method and system for externally treating the blood
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4748120A (en) * 1983-05-02 1988-05-31 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
IT1169415B (it) * 1983-05-09 1987-05-27 Jean Jacques Goupil Prodotti medicinali contenenti un derivato del psoralene
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4704352A (en) 1985-06-25 1987-11-03 Baxter Travenol Laboratories, Inc. L-ascorbate-2-phosphate salts in blood cell storage
US5055485A (en) * 1988-12-02 1991-10-08 New York Blood Center, Inc. Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides
US5356929A (en) * 1989-01-23 1994-10-18 Lehigh University Reduced and quaternized psoralens as photo-activated therapeutics
US5342752A (en) 1990-04-16 1994-08-30 Cryopharm Corporation Method of inactivation of viral blood contaminants using acridine deriatives
AU6859394A (en) 1993-05-25 1994-12-20 Auckland Uniservices Limited Nitrobenzyl mustard quaternary salts and their use as hypoxia-selective cytotoxic agents
US5399719A (en) * 1993-06-28 1995-03-21 Steritech, Inc. Compounds for the photodecontamination of pathogens in blood
EP0739163A1 (de) 1994-01-10 1996-10-30 Hemasure, Inc. Inaktivierung von virus in blutkomponenten unter verwendung chemisch aktivierter verbindungen
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
DE4444045C2 (de) 1994-12-10 1997-04-17 Behringwerke Ag Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten
US6177441B1 (en) * 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
AU722811B2 (en) * 1995-06-07 2000-08-10 Cerus Corporation Treating red blood cell solutions with anti-viral agents
CA2198085A1 (en) 1995-06-29 1997-01-23 Hemasure, Inc. Inactivation of pathogens using hydroxymethylamines
US6114108A (en) 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
US6136586A (en) 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6093564A (en) 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents

Also Published As

Publication number Publication date
JP3145124B2 (ja) 2001-03-12
US5691132A (en) 1997-11-25
US6143490A (en) 2000-11-07
US20020182581A1 (en) 2002-12-05
DE69533942D1 (de) 2005-02-24
JPH10507367A (ja) 1998-07-21
AU4151396A (en) 1996-06-06
CA2203885C (en) 2007-01-09
EP0804074A4 (de) 1999-12-08
WO1996014737A1 (en) 1996-05-23
DE69533942T2 (de) 2005-12-29
US6171777B1 (en) 2001-01-09
EP0804074A1 (de) 1997-11-05
EP0804074B1 (de) 2005-01-19
AU712034B2 (en) 1999-10-28
US5559250A (en) 1996-09-24
US6410219B1 (en) 2002-06-25
CA2203885A1 (en) 1996-05-23

Similar Documents

Publication Publication Date Title
ATE287210T1 (de) Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen
ATE243198T1 (de) Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen
DE19775096I2 (de) Desulfatohirudine Verfahren zu ihrer Herstellung und pharmazeutische Mittel
DE3787445D1 (de) Verfahren zur Isolierung von langkettiger Nukleinsäure.
DE3783282D1 (de) Varianten von lav-viren, deren dns- und proteinkomponenten und deren verwendung, insbesondere zu diagnostischen zwecken und zur herstellung von immunogenen zusammensetzungen.
DK43890D0 (da) Nucleinsyre, vektorer og celler indeholdende den, derudfra fremstillede produkter og disses anvendelse
Schoelmerich et al. Zinc and vitamin A deficiency in patients with Crohn's disease is correlated with activity but not with localization or extent of the disease
EP1162457A3 (de) Vielfach-Koagulationstestsystem und Verfahren zu seiner Anwendung
ATE5749T1 (de) Verfahren und diagnostisches mittel zur direkten bestimmung des lipidgehaltes der betalipoproteine des blutes.
ATE108906T1 (de) Methode zur bestimmung des verhaltens von medikamenten in lebewesen.
ATA77095A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen, enthaltend eine aktive gerinnungsfördernde stubstanz
RU95120165A (ru) Лекарственный препарат иммунозамещающего действия на основе клеточной суспензии и способ лечения синдрома приобретенного иммунодефицита (вич-инфекции) с использованием этого препарата
Ogston et al. Studies on the clot-promoting effect of skin
FI971879A0 (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
RU2202363C2 (ru) Способ определения чувствительности живого организма и/или его клеток к воздействию вещества, поля или комбинации веществ и/или полей
RU2145874C1 (ru) Способ получения некрэктомирующей повязки
Hayakawa et al. Studies on the risk factors for fenofibrate-induced elevation of liver function tests
Fernelius Development of a burn treatment
DE3776662D1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
Hain Pregnandiol Excretion in Pregnancy Disorders
UA33564A (uk) Спосіб підготовки проб біорідин для визначення вмісту речовин ліпідної природи
Gruber et al. Experience of using a B. licheniformis plate for a better detection of sulphonamides with the biological inhibitor test.
Nem Effect of adequacy of perfusion and functional state of the liver on the changes of protein content of blood and certain indicators of nitrogen metabolism in patients operated on for tetralogy of Fallot
JPS5646893A (en) Novel protein capable of combining with deoxyribonucleic acid in blood having close relationship with cancer, isolating and purifying method of the same and clinical application of the same
RU94009653A (ru) Способ коррекции метаболических процессов в клетке

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties